Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — IPO Roadshow (November 2021)
26 slides from Heartbeam's IPO roadshow presentation, Nov 1, 2021
Slide 1: Medical Grade Heart Attack Detection Always with the patient
Medical Grade Heart Attack Detection Always with the patient Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration no. 333 - 259358 Relating to Preliminary Prospectus dated October 12, 2021
Slide 2: Forward-looking statements and market data
This presentation includes forward - looking statements that involve substantial risks and uncertainties . All statements, other than statements of historical facts, included in this presentation regarding forward - looking statements . The words “believe”, “anticipate”, “intend”, “expect”, “target”
Slide 3: Statement About Free Writing Prospectus
STATEMENT ABOUT FREE WRITING PROSPECTUS This free writing prospectus relates to the proposed initial public offering of common stock of HeartBeam, Inc., which are be ing registered on a registration statement on Form S - 1 (File No. 333 - 259358) (the “Registration Statement”). This free writing pro
Slide 4: The Offering
THE OFFERING Issuer HeartBeam, Inc. Offering Type Initial Public Offering Securities Offered Unit comprising 1 Common Stock and [ ] Warrants immediately separated upon issuance Price Range $5.50 - $6.50 Shared Offered 2,750,000 shares plus 15%, 30 - day overallotment option Gross Proceeds $16.5 Mill
Slide 5: About Us
ABOUT US RICH FERRARI Over 40 years of experience in Medical Device Start - ups Co - founder of De Novo Ventures which has $650M under management Executive Chairman BRANISLAV VAJDIC Founder of HeartBeam Over 30 years of experience in technology development and senior management positions Chief Execu
Slide 6: HeartBeam Investment Highlights
HEARTBEAM INVESTMENT HIGHLIGHTS BREAKTHROUGH TECHNOLOGY FOR TELEHEALTH, A RAPIDLY EXPANDING AREA OF MEDICINE $10bn+ Ability to become standard of care in Emergency Medicine and Cardiology Robust clinical data demonstrated in studies designed by world - class scientific leaders Strong IP Portfolio, w
Slide 7: Patients cannot determine if they are having a heart attack
82 % Cost to the healthcare system each year $10B $ Patients delay an average of 3 hours before seeking care Delays lead to increased mortality Greater incidence of heart failure among these patients for an average wait 3 - 4 hours after symptoms begin Mortality rate increases by 40 % Wasted healthc
Slide 8: HeartBeam US Market Opportunity
AFib Patients Prior MI Patients $4+ billion 1. National Hospital Ambulatory Medical Care Survey: 2016 Emergency Department Summary Tables 2. Unplanned Readmission Within 6 Months Affects 25% of PCI Patients in the US. TCTMD 2019 3. Bayoumy et. Al. Smart Wearable Devices in cardiovascular care: where
Slide 9: HeartBeam Solutions
ER Software Complete telehealth solution for remote MI monitoring ER solution for more accurate MI detection Q3 2022 Q1 2023 HEARTBEAM SOLUTIONS TRUE PLATFORM TECHNOLOGY PRODUCTS Telehealth 9
Slide 10: Telehealth Solution: The Core Product
TELEHEALTH SOLUTION THE CORE PRODUCT TELEHEALTH SOLUTION Q1 2023 Telehealth Complete telehealth solution for remote MI monitoring 10
Slide 11: HeartBeam Prescription-Based Telehealth Solution
Physician views 12 - lead ECG & diagnostic suggestion. Directs patient. Physician Portal Diagnostic suggestion & synthesized 12 - lead ECG overlaid with baseline HeartBeam Cloud 3D Vector ECG Device Patient places credit card size device on chest for 30 sec signal recording Smartphone Application Si
Slide 12: Credit Card Sized ECG Machine
CREDIT CARD SIZED ECG MACHINE 12 - LEAD ECG SYSTEM ALWAYS WITH PATIENT EJECTED CHEST ELECTRODES NOT IN USE: PLANAR IN USE BY PATIENT BATTERY RECHARGE FREQUENCY 30 DAYS VIA USB CABLE WEIGHT 28G. (1 OZ.) HEIGHT AND WIDTH CREDIT CARD SIZE THICKNESS 4MM (1/8 INCH) DEVICE Ejected chest electrodes Retract
Slide 13: HeartBeam Technology Breakthrough
DIAGNOSTIC ENGINE HeartBeam delivers powerful and accurate diagnostic suggestions through a novel algorithm that uses highly accurate ECG interpretation, symptoms and risk factors. HEARTBEAM TECHNOLOGY BREAKTHROUGH 3D ECG SIGNAL DIAGNOSTIC CREDIT CARD SIZED DEVICE A unique approach captures the hear
Slide 14: Three Harvard-Designed Studies
THREE HARVARD - DESIGNED STUDIES EXCELLENT PERFORMANCE HIDES STUDY N = 186 recordings; 66 subjects ACCURACY Unique 3D ECG interpretation method has greater accuracy than cardiologists in detecting MI’s 93 % 72 % Cardiologist B SCORE ER STUDY N = 110 subjects SENSITIVITY Proprietary algorithm perform
Slide 15: Key Medical Contributors
KEY MEDICAL CONTRIBUTORS MIKE GIBSON, MD PETER ZIMETBAUM, MD ALEXEI SHVILKIN, MD NIRAJ VARMA, MD PHILIP SAGER, MD RAJ DASH, MD TOM DEERING, MD JOHN JEFFERIES, MD CHARLIE BROWN, MD JEFFREY J. OYLER, MD BARRY MANGEL, MD TEAM 15
Slide 16: Market Landscape
Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection MARKET LANDSCAPE SUBSTANTIAL CAPABILITIES BEYOND EXISTING OFFERINGS COMPETITION 16
Slide 17: Telehealth Product Development and Regulatory Plan
Credit card sized collection device Smartphone app Synthesized baseline + symptomatic 12L ECGs for physician’s review Symptoms report Patient risk factors/history TELEHEALTH PRODUCT DEVELOPMENT AND REGULATORY PLAN FDA 510(K) Predicate devices identified Simple validation study Will provide data on a
Slide 18: Telehealth Product Reimbursement Strategy
Excellent alignment with CAD patient needs TELEHEALTH PRODUCT REIMBURSEMENT STRATEGY USE AVAILABLE RPM CODES TO ACCELERATES REVENUE AND DATA COLLECTION REIMBURSEMENT Subscription Model To HeartBeam Reimbursement To Practice $600/year ($50/month) per patient $1,300+/year ($110/month) per patient *Rem
Slide 19: HeartBeam Solution: ER Software Product
HEARTBEAM SOLUTION ER SOFTWARE PRODUCT ER SOLUTION ER Solution for more accurate MI detection ER Software Q3 2022 19
Slide 20: ER Software Product: First Revenues
ER SOFTWARE PRODUCT FIRST REVENUES 5,000 ER & Chest Pain Centers Software licensing business model drives $ 100k/year per ER HeartBeam will use its own sales force HeartBeam ’s s oftware - only heart attack diagnosis tool for the ER improves accuracy of MI diagnosis 93 % 72 % Cardiologist panel 21 -
Slide 21: ER Software and Gen 1 Telehealth Revenue Opportunity
ER SOFTWARE AND GEN. 1 TELEHEALTH REVENUE OPPORTUNITY REVENUE HeartBeam will use its own salesforce Software licensing business model drives $100k/ yr per ER x ER averages 85 patients/day x ECG for all patients $3 - 4/use HeartBeam will use its own salesforce Excellent alignment w/ CAD patient needs
Slide 22: Product Launch Timeline
Development of FDA - ready product complete Submission FDA ER study completed Clearance Q1 2022 Q3 2022 Submission FDA study completed Clearance Development of FDA - ready product complete Q4 2022 Q4 2021 ER SOFTWARE TOOL TELEHEALTH Q2 2022 Launch PRODUCT LAUNCH TIMELINE FDA Product Development FDA
Slide 23: Deep Product Pipeline
Application for MI ECG detection in ER Basic RPM Solution Gen 1 Telehealth Software from Telehealth system 12 - lead ECG patch PLATFORM TECHNOLOGY DEEP PRODUCT PIPELINE 12 - lead recording and real time signal transmissions AI Solution Longitudinal big data set TODAY FUTURE PRODUCTS Complete system
Slide 24: Highly Experienced Management
Branislav Vajdic, PhD CEO & Founder Alexei Shvilkin, MD Chief Medical Officer Dorin Panescu, PhD Chief Technical Officer Wim Elfrink Board Member Rich Ferrari Executive Chairman Rick Brounstein CFO Alan Baumel COO Jon Hunt, PhD Chief Business Officer George de Urioste Board Member TEAM HIGHLY EXPERI
Slide 25: HeartBeam Investment Highlights
HEARTBEAM INVESTMENT HIGHLIGHTS BREAKTHROUGH TECHNOLOGY FOR TELEHEALTH, A RAPIDLY EXPANDING AREA OF MEDICINE $10bn+ Ability to become standard of care in Emergency Medicine and Cardiology Robust clinical data demonstrated in studies designed by world - class scientific leaders Strong IP Portfolio, w
Slide 26: Thank you!
Thank you! Heart Beam —